Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results
{{output}}
Background: Flu-like symptoms are common adverse events associated with interferon beta relapsing multiple sclerosis therapies. Objectives: To ... ...
